Immix Biopharma (IMMX) News Today

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

$2.21

-0.29 (-11.60%)

(As of 04/18/2024 ET)

Source

Source	Headline
	Immix Biopharma, Inc. (IMMX) finance.yahoo.com - April 18 at 11:00 PM
	Immix Biopharma, Inc.: Immix Biopharma on Track to Dose NXC-201 Patients in United States finanznachrichten.de - April 18 at 6:00 PM
	Immix Biopharma on Track to Dose NXC-201 Patients in United States globenewswire.com - April 18 at 9:32 AM
	Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) globenewswire.com - April 15 at 9:36 AM
	IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023 investorplace.com - April 2 at 8:06 AM
	Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial globenewswire.com - March 20 at 9:46 AM
	Immix Biopharma Announces "Be Proactive in AL" AL Amyloidosis Awareness Initiative stockhouse.com - March 7 at 7:29 PM
	Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative globenewswire.com - March 5 at 9:35 AM
	Immix Biopharma (IMMX) Price Target Increased by 27.27% to 14.28 msn.com - February 24 at 11:20 PM
	IMMX Apr 2024 7.500 call finance.yahoo.com - February 22 at 7:52 PM
	Immix Biopharma, Inc.: Immix Biopharma 12 Month Review Progress Update finanznachrichten.de - February 21 at 2:15 PM
	Immix Biopharma 12 Month Review Progress Update markets.businessinsider.com - February 21 at 2:15 PM
	Immix Biopharma 12 Month Review Progress Update finance.yahoo.com - February 21 at 2:15 PM
	Immix Biopharma 12 Month Review Progress Update globenewswire.com - February 21 at 9:31 AM
	IMMX Aug 2024 2.500 call finance.yahoo.com - February 13 at 7:56 AM
	Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock finance.yahoo.com - February 8 at 7:18 PM
	Immix Biopharma, Inc.: Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis finanznachrichten.de - February 8 at 2:17 PM
	Immix Biopharma Signs Definitive $15M Titan Partnership Deal markets.businessinsider.com - February 7 at 12:40 PM
	Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis finance.yahoo.com - February 7 at 12:40 PM
	Immix Biopharma Suspends Stock Offering Pending New Prospectus msn.com - February 6 at 10:20 AM
	Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock finance.yahoo.com - February 5 at 11:42 PM
	Immix Biopharma Announces Proposed Public Offering of Common Stock finance.yahoo.com - February 5 at 6:41 PM
	marketbeat.com - February 5 at 3:35 PM
	marketbeat.com - February 5 at 3:35 PM
	Immix Biopharma Reveals FDA Labeling Change Notification For CAR-T Products markets.businessinsider.com - January 24 at 7:27 PM
	Immix Biopharma, Inc.: Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products finanznachrichten.de - January 24 at 2:27 PM
	Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products finance.yahoo.com - January 24 at 2:27 PM
	Immix Biopharma, Inc. (NASDAQ:IMMX) Sees Large Increase in Short Interest marketbeat.com - January 15 at 2:56 AM
	Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Expands By 52.3% marketbeat.com - January 13 at 8:35 AM
	Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth? finance.yahoo.com - January 11 at 8:48 AM
	Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board finance.yahoo.com - January 4 at 10:11 AM
	Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board finance.yahoo.com - December 18 at 1:12 PM
	Insider Spends US$267k Buying More Shares In Immix Biopharma finance.yahoo.com - December 15 at 9:13 AM
	Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023 finance.yahoo.com - December 11 at 2:02 PM
	Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit finance.yahoo.com - November 30 at 10:39 AM
	What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing' finance.yahoo.com - November 28 at 4:16 PM
	Pleasing Signs As A Number Of Insiders Buy Immix Biopharma Stock finance.yahoo.com - November 24 at 9:15 AM
	Immix to assess cell therapy in Phase Ib/IIa AL amyloidosis trial msn.com - November 22 at 2:48 PM
	Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis finance.yahoo.com - November 22 at 2:48 PM
	FDA okays US clinical testing for Immix drug NXC-201 msn.com - November 21 at 2:33 PM
	Immix Biopharma Announces FDA IND Clearance For CAR-T NXC-201 markets.businessinsider.com - November 21 at 2:33 PM
	Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing finance.yahoo.com - November 21 at 2:33 PM
	Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients finance.yahoo.com - November 6 at 1:05 PM
	Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients finance.yahoo.com - November 6 at 1:05 PM
	Here's Why Immix Biopharma, Inc. (IMMX) Is a Great 'Buy the Bottom' Stock Now finance.yahoo.com - October 31 at 12:34 PM
	Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board finance.yahoo.com - October 26 at 10:12 AM
	Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site finance.yahoo.com - October 16 at 12:53 PM
	Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting finance.yahoo.com - October 3 at 1:37 PM
	marketbeat.com - October 3 at 9:37 AM
	What's Going On With Cancer-Focused Immix Biopharma Stock Today? msn.com - October 2 at 4:06 PM

Get Immix Biopharma News Delivered to You Automatically

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

IMMX Media Mentions By Week

IMMX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IMMX
News Sentiment
▼
0.00

0.53
▲
Average
Medical
News Sentiment

IMMX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IMMX Articles
This Week
▼
4

1
▲
IMMX Articles
Average Week

Get Immix Biopharma News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:IMMX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Immix Biopharma (IMMX) News Today

IMMX Media Mentions By Week

IMMX Media Sentiment

IMMX News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info